The Accelerating Medicines Partnership is a public-private collaboration among the National Institutes of Health, pharmaceutical companies, and non-profit organizations.

This program aims to advance novel vaccine adjuvants toward licensure for human use. The program supports the optimization of adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.

The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.

In 2013, NIAID launched the Antibacterial Resistance Leadership Group (ARLG), a major clinical effort to address antibacterial resistance (AR).

The AADCRC program is the cornerstone of NIAID efforts to promote multidisciplinary basic and clinical research on the immunological basis, pathobiology, diagnosis, treatment, and preven​tion of asthma and allergic diseases.

The Atopic Dermatitis Research Network is a consortium of academic medical centers that conduct clinical research studies in an attempt to learn more about skin infections associated with atopic dermatitis.

The ACEs conduct collaborative basic and clinical research on autoimmune diseases. Close interaction between clinicians and basic researchers accelerates the discovery, development, and translation of therapies for autoimmune diseases from the lab to use in the clinic.

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.

The Bioinformatics and Computational Biosciences Branch (BCBB) drives innovation in biomedical informatics at the NIAID for global health clinicians and researchers by fostering a pipeline of products, platforms, and solutions.

The Bioinformatics Resource Centers (BRCs) for Infectious Diseases program was initiated in 2004 with the main objective of collecting, archiving, updating, and integrating a variety of research data and providing such information through user friendly interfaces and computational analysis tools to be made freely available to the scientific community.

The Center for Advanced Tissue Imaging (CAT-I) is an NIAID and NCI supported effort involving collaborative studies between experts in the Laboratory of Immune System Biology, DIR, NIAID and investigators in the DIR, NIAID and CCR, NCI.

Read more about the Center for Advanced Tissue Imaging (CAT-I).

CHAVI-ID are two consortiums established by NIAID to undertake the immunologic research required to tackle the major scientific obstacles in the development of an effective HIV vaccine. The two seven-year awards were made in 2012, one to Duke University and a second to The Scripps Research Institute.

CIDI is a partnership between NIAID and Radiology and Imaging Sciences at the National Institutes of Health Clinical Center. It was established to perform basic science, translational, and clinical research on the imaging features of infectious disease.

The Centers for AIDS Research (CFAR) program at the National Institutes of Health provides administrative and shared research support to synergistically enhance and coordinate high quality AIDS research projects. CFARs accomplish this through core facilities that provide expertise, resources, and services not otherwise readily obtained through more traditional funding mechanisms.

The National Institute of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) program is an integrated network of centers designed to bring together multidisciplinary teams of researchers that perform surveillance related research integrated with research on host immune response, viral pathogenesis, and the factors that control the emerg

In 2014, NIAID established the Centers of Excellence for Translational Research (CETR) program. Supported translational activities will range from very early discovery-based efforts to late-stage preclinical development.

The Clinical Islet Transplantation Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.

The Clinical Trials in Organ Transplantation (CTOT) program is an investigative consortium that conducts clinical and associated mechanistic studies to improve outcomes for transplant recipients.

The Clinical Trials in Organ Transplantation in Children (CTOT-C) program focuses on the specific challenges associated with pediatric organ transplantation. This program is a continuation of the first NIAID pediatric transplantation clinical trial consortium, the Cooperative Clinical Trials in Pediatric Transplantation program.

Community Partners (CP) works to promote effective representation of the many US-based and international communities in which the NIH-funded HIV Clinical Trials Networks conduct research.

The Consortium of Food Allergy Research (CoFAR) was established in fiscal year (FY) 2005 to support clinical research on food allergy. It was renewed in FY 2010 to continue several promising clinical studies from the original consortium and expanded to include research on the genetic causes underlying food allergy and the mechanisms of food allergy-associated eosinophilic esophagitis.

The long-term goal of the Cooperative Centers on Human Immunology (CCHI) program is the translation of immunology research into clinical applications in humans in the area of infectious disease.

The purpose of the Creative and Novel Ideas in Research (CNIHR) Program is to create a mechanism via the established Centers for AIDS Research (CFARs) to fund developmental projects to bring insight and new ideas from early-stage investigators, some of whom will have expertise in other disciplines, to the HIV/AIDS field of study.

The Division of AIDS (DAIDS) maintains contracts that can potentially provide limited pre-clinical services including manufacturing, analytical chemistry, preclinical pharmacology and toxicology resources to investigators who are working on the development of therapeutics targeting HIV/AIDS and AIDS-related opportunistic infections, including TB.

The Division of AIDS (DAIDS) offers a unique venture to enable, facilitate, operationalize and translate vaccine developers’ concepts into current good manufacturing practice (cGMP)-manufactured, vialed products for clinical trials.

European and Developing Countries Clinical Trials Partnership (EDCTP)  funds research for prevention and treatment of HIV/AIDS, tuberculosis, malaria, and neglected infectious diseases in sub-Saharan Africa.

The Functional Genomics Program for understanding the functions of uncharacterized genes in infectious disease pathogens aims to generate experimental data to determine the biochemical function(s) of hypothetical genes, unknown open reading frames, and noncoding RNAs.

The NIAID Genomic Centers for Infectious Diseases (GCID) provide insights into the biology of microbes, their role in pathogenesis, and their interactions with the host, including the microbiome, by supporting a diverse set of genomic capabilities, such as next-generation sequencing and related genomic technologies.

NIAID supports and complies with the data sharing policies, including the NIH Genomic Data Sharing (GDS) Policy

An effective and widely available vaccine will be central to any global strategy to slow and end the HIV pandemic.

The mission of the NIAID Intramural Collaborative Program in Global Neglected Infectious Diseases (GNID) is to seek fundamental understanding of neglected infectious diseases and to promote scientific interactions among NIAID investigators engaged in research on neglected tropical diseases (NTDs) and related infections, listed on Neglect

The HIV Prevention Trials Network develops and tests the safety and efficacy of primarily non-vaccine interventions designed to prevent the transmission of HIV.

The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.

The NIAID HIV/AIDS Clinical Trials Networks have been designed to address NIAID’s five HIV/AIDS scientific priorities.

The Networks inlcude:

This purpose of this program is to understand how the human leukocyte antigen (HLA) gene region and killer immunoglobulin-like receptor gene family are associated with immune-mediated diseases.

The Human Immunology Project Consortium (HIPC) is a network of researchers established to create a public resource that characterizes the diverse states of the human immune system. HIPC investigators use modern analytic tools to profile the immune system before and after infection, vaccination, or treatment with an adjuvant.

Co-sponsored by NIAID and the Juvenile Diabetes Research Foundation International, the ITN is an international consortium of basic scientists and clinical investigators that performs clinical research to evaluate the safety and efficacy of methods that can induce the immune system to tolerate certain antigens for the treatment of immune-mediated disorders.

The Immunity in Neonates and Infants Program supports research of the developing immune system during the first year of life. This program encourages the use of innovative approaches using human infant tissues and cells, or relevant animal models, to define pathways and mechanisms that contribute to the immune status of the neonate and infant.

The Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP) aims to develop preclinical porcine to nonhuman primate models of islet, kidney, heart, lung, or liver xenotransplantation.

The primary clinical goals of this multi-center clinical trial on HIV+ kidney transplant recipients are to evaluate the impact of CCR5 blockade (maraviroc, MVC) on renal function at week 52 post-transplant; as well as evaluate the overall safety and tolerability of CCR5 blockade in the HIV+ kidney transplant recipient.

The INA-RESPOND is a collaboration between NIAID, the National Institute of Health Research and Development, Ministry of Health of the Republic of Indonesia, and ten major university and clinical centers in Indonesia.

The Indo-U.S. Vaccine Action Program (VAP) is a bilateral program, which supports a broad spectrum of activities relating to immunization and vaccine related research. The program was designed to encompass laboratory-based research, epidemiological studies, field trials, vaccine quality control, and delivery of vaccines.

The IDCRP works to substantially reduce the impact of infectious diseases in the military population through a unique, adaptive, collaborative clinical research network. The IDCRP conducts infectious disease clinical research that is important to the military for informing health policy and clinical practice, and disseminates findings throughout the scientific community.

Inner-City Asthma Consortium (ICAC) focuses on understanding how the environment, allergens, and genetics interact with the body’s immune system to cause asthma and aggravate its symptoms.

 The ICEMRS are a global network of independent research centers in malaria-endemic settings, established by NIAID to provide the knowledge, tools, and evidence-based strategies crucial to understanding, controlling, and, ultimately, preventing malaria.

The IeDEA Cohort Consortium collaborates to collect and define key variables, harmonize data, and implement methodology to effectively pool data as a cost-effective means of generating large data sets.

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is a global collaboration of investigators, institutions, community representatives and other partners organized for the purpose of evaluating interventions to treat and prevent HIV infection and its consequences in infants, children, adolescents, and pregnant/postpartum women through the conduct of high qual

The mission of the Division of Intramural Research (DIR) Malaria Research Program (MRP) is to seek fundamental knowledge about the interactions of malaria parasites with the human host and the mosquito vectors that transmit them and to apply this knowledge to prevent disease, enhance health, and improve the quality of life in malaria endemic areas. 

UCRC is an initiative between the Malian Ministry of Health, the Ministry of Higher Education, University of Science, Technology and Technology of Bamako (USTTB) and NIAID.  The purpose of the collaboration is to enhance the infrastructure and resources needed to facilitate clinical research in Mali.  NIAID has had a longstanding partnership with the USTTB.

In response to the outbreak of the H1N1 pandemic in 2009, the Ministry of Health of Mexico identified the need to create a clinical research network with the mission to lead and promote discoveries and advances in the field of emerging infectious disease.  The resulting network, the Mexican Emerging Infectious Disease Clinical Research Network (La Red), was established in September 2009.  Ten i

The Microbicide Trials Network (MTN) is an NIAID-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV.

The NIAID Modeling Immunity for Biodefense (MIB) program brings together immunologists, microbiologists, bioinformaticians, and modelers to advance our understanding of the complex immune mechanisms triggered by infection and/or vaccination.

This program supports the discovery and analysis of combination adjuvants. Combining different adjuvants can improve the immune response that a vaccine induces and the protection it provides. However, little is known about how to best combine different adjuvants to optimize vaccine efficacy.

The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men conducted by sites located in Baltimore, Chicago, Pittsburgh and Los Angeles. Biological and behavioral data are collected every six months from study participants.

The NIAID Clinical Genomics Program at the National Institutes of Health (NIH) is ​a broadly collaborative program that builds upon large-scale gene sequencing analysis to promote multi-disciplinary, cutting-edge basic and clinical genomics research. Our goal is to accelerate research aimed at better understanding, diagnosing, and treating disorders of the immune system.

CSGADP was established in 2001 as a collaborative network of investigators with a focus on halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression with an emphasis on Type 1 diabetes.

The Division of AIDS (DAIDS) supports a number of programs, networks, and studies to increase basic knowledge of the pathogenesis and transmission of HIV, promote the development of therapies for HIV infection and its complications and co-infections, and encourage the development of vaccines and other prevention strategies.

The NIAID Microbiome Program is a collaborative effort to explore the metaorganism using existing and new facilities and personnel. The program has developed a microbiome sequencing facility with bioinformatics support and a gnotobiotic mouse facility, and is currently expanding microbiology resources.

The North American Cysticercosis Consortium was formed in 2009 to promote collaboration and sharing of resources in the study of neurocysticercosis among clinicians and research scientists in North America. An estimated 1,500 cases of neurocysticercosis are diagnosed each year in the United States.

Addressing complex public health issues requires the combined efforts of government agencies, academic institu​tions, private-sector companies, and nonprofit organizations. Such partnerships help leverage resources, improve efficiency and cost-effectiveness, and increase the feasibility and scientific impact of the research.

The Partnership of Clinical Research in Guinea (PREGUI) was established between the Government of Guinea and the United States. The Government of Guinea is represented through the Ministry of Health (MOH).

The Pox-Protein Public Private Partnership (P5) – comprised of the Bill & Melinda Gates Foundation, the National Institutes of Health, Sanofi Pasteur, GlaxoSmithKline (GSK), the South African Medical Research Council, the HIV Vaccine Trials Network (HVTN), and the US Military HIV Research Program – is a diverse group of organizations committed to building upon the modest protective efficacy

The Structural Genomics Centers for Infectious Diseases (SGCID) apply state-of-the-art high-throughput technologies and methodologies to experimentally characterize the three dimensional (3-D) atomic structure of proteins or other molecules that play an important biological role in human pathogens and infectious diseases, especially those in the

The Systems Approach to Immunity and Inflammation Program conducts forward genetic screens of mutant or genetically diverse mice, combined with systems level analysis, to identify previously unappreciated key immune regulatory genes, signaling pathways, or mechanisms; and includes validation of these pathways in human cells and tissues.

The NIAID/Division of Microbiology and Infectious Diseases (DMID) Systems Biology Consortium for Infectious Diseases is a group of interdisciplinary scientists that bridge disparate scientific disciplines including microbiology, immunology, infectious diseases, microbiome, mathematics, physics, bioinformatics, computational biology, machine learning, statistical methods, and mathematical modeli

This program supports novel T-cell epitope identification, characterization and validation of important food allergens and aeroallergens that have not been previously studied.

The Technology Transfer and Intellectual Property Office (TTIPO) facilitates collaborative relationships between NIAID investigators and the broader scientific community. TTIPO staff members are experts in technology transfer and intellectual property and are NIAID’s main resource for negotiating technology transfer agreements.

The Trans-NIH Microbiome Working Group (TMWG) was established in 2012 by Dr. Lita Proctor (NHGRI) to provide a forum for coordinating NIH extramural research activities related to the human microbiome. TMWG membership is open to all extramural program staff from ICs with an interest in the human microbiome. The TMWG meets monthly.

NIAID awarded the Tropical Medicine Research Centers (TMRCs) in 1991 to establish international research sites in disease-endemic countries. The program was renewed in 2017, with the funding of seven Centers (five new Centers and two renewals).

First established in 1994, the Tuberculosis Research Units Network (TBRU-N) integrates scientific and clinical research disciplines to study aspects of human TB in endemic countries. The Network is comprised of four multi-project awards to study TB latency and persistence and their relation to active TB disease in humans.

The U.S. Military HIV Research Program (MHRP) was established in 1985 to protect U.S. troops entering endemic HIV areas and is dedicated to HIV vaccine development, prevention, disease surveillance, and HIV care and treatment. NIAID plans and executes HIV/AIDS research projects annually with MHRP through an interagency agreement on HIV vaccine research.

PEPFAR is the U.S. government initiative to help save the lives of those living with and affected by HIV/AIDS around the world. This historic commitment is the largest by any nation to combat a single disease internationally, and PEPFAR investments also help alleviate suffering from other diseases across the global health spectrum.

The United States Immunodeficiency Network, a NIH-funded research program of the Immune Deficiency Foundation, was established to advance scientific research in primary immunodeficiency (PI) diseases.

The Vaccine and Treatment Evaluation Units (VTEUs) have played a key role in NIAID’s effort to develop new and improved vaccines and therapies against infectious diseases for over four decades. They have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure.

The Women's Interagency HIV Study (WIHS), established in 1993, is a multi-center, prospective, observational cohort study of women living in the United States who are either HIV-infected or at risk for HIV acquisition.  WIHS plays an important role in NIAID’s effort to understand the current epidemiology of HIV infection, disease progression, treatment use and outcomes, and related co-morbiditi